Home › Compare › PKBOW vs EQR

PKBOW vs EQR: Dividend Comparison 2026

PKBOW yields 20202.02% · EQR yields 4.73%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 PKBOW wins by $57988137149625106432.00M in total portfolio value
10 years
PKBOW
PKBOW
● Live price
20202.02%
Share price
$0.01
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$57988137149625106432.00M
Annual income
$57,428,928,743,751,610,000,000,000.00
Full PKBOW calculator →
EQR
EQR
● Live price
4.73%
Share price
$58.58
Annual div
$2.77
5Y div CAGR
15.8%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$40.5K
Annual income
$3,819.61
Full EQR calculator →

Portfolio growth — PKBOW vs EQR

📍 PKBOW pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodPKBOWEQR
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, PKBOW + EQR cover 0 of 12 months — good coverage

Jan
—
Feb
—
Mar
—
Apr
—
May
—
Jun
—
Jul
—
Aug
—
Sep
—
Oct
—
Nov
—
Dec
—
PKBOW pays
EQR pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

PKBOW
Annual income on $10K today (after 15% tax)
$1,717,171.72/yr
After 10yr DRIP, annual income (after tax)
$48,814,589,432,188,870,000,000,000.00/yr
EQR
Annual income on $10K today (after 15% tax)
$401.93/yr
After 10yr DRIP, annual income (after tax)
$3,246.67/yr
At 15% tax rate, PKBOW beats the other by $48,814,589,432,188,870,000,000,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of PKBOW + EQR for your $10,000?

PKBOW: 50%EQR: 50%
100% EQR50/50100% PKBOW
Portfolio after 10yr
$28994068574812553216.00M
Annual income
$28,714,464,371,875,805,000,000,000.00/yr
Blended yield
99.04%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on EQR right now

PKBOW
No analyst data
Altman Z
-52.0
Piotroski
2/9
EQR
Analyst Ratings
16
Buy
28
Hold
2
Sell
Consensus: Hold
Price Target
$70.35
+20.1% upside vs current
Range: $63.00 — $78.50
Altman Z
1.8
Piotroski
7/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

PKBOW buys
0
EQR buys
0
No recent congressional trades found for PKBOW or EQR in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricPKBOWEQR
Forward yield20202.02% ✓4.73%
Annual dividend / share$2.00$2.77 ✓
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%15.8% ✓
Portfolio after 10y$57988137149625106432.00M ✓$40.5K
Annual income after 10y$57,428,928,743,751,610,000,000,000.00 ✓$3,819.61
Total dividends collected$57951242634511319040.00M ✓$16.9K
Payment frequencyquarterlyquarterly
SectorStockREIT

Year-by-year: PKBOW vs EQR ($10,000, DRIP)

YearPKBOW PortfolioPKBOW Income/yrEQR PortfolioEQR Income/yrGap
1← crossover$2,030,902$2,020,202.02$11,248$547.57+$2.02M → PKBOW
2$385,615,342$383,442,277.01$12,701$666.53+$385.60M → PKBOW
3$68,455,310,249$68,042,701,832.74$14,405$814.59+$68455.30M → PKBOW
4$11,362,120,801,776$11,288,873,619,809.51$16,413$999.84+$11362120.79M → PKBOW
5$1,763,290,309,334,738$1,751,132,840,076,837.00$18,795$1,232.92+$1763290309.32M → PKBOW
6$255,866,846,080,109,380$253,980,125,449,121,180.00$21,639$1,527.95+$255866846080.09M → PKBOW
7$34,717,188,276,404,167,000$34,443,410,751,098,450,000.00$25,057$1,903.80+$34717188276404.14M → PKBOW
8$4,404,848,409,251,598,600,000$4,367,701,017,795,846,700,000.00$29,197$2,385.87+$4404848409251598.50M → PKBOW
9$522,624,678,386,435,660,000,000$517,911,490,588,536,450,000,000.00$34,250$3,008.70+$522624678386435648.00M → PKBOW
10$57,988,137,149,625,104,000,000,000$57,428,928,743,751,610,000,000,000.00$40,467$3,819.61+$57988137149625106432.00M → PKBOW

PKBOW vs EQR: Complete Analysis 2026

PKBOW — Stock

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics addressing unmet needs in the areas of oncology and inflammation. The company's proprietary toxin, PH-1 or Thailanstatin, a spliceosome modulator is being used to generate its first pipeline of novel ADC product candidates to address unmet needs in cancer patients. Its lead product candidate, PHP-303, is a small molecule awaiting Phase II dose clinical study in the orphan disease Alpha1 anti-trypsin deficiency (AATD). The company is based in Palo Alto, California.

Full PKBOW Calculator →

EQR — REIT

Equity Residential is committed to creating communities where people thrive. The Company, a member of the S&P 500, is focused on the acquisition, development and management of residential properties located in and around dynamic cities that attract high quality long-term renters. Equity Residential owns or has investments in 305 properties consisting of 78,568 apartment units, located in Boston, New York, Washington, D.C., Seattle, San Francisco, Southern California and Denver.

Full EQR Calculator →
📬

Get this PKBOW vs EQR comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

PKBOW vs SCHDPKBOW vs JEPIPKBOW vs OPKBOW vs KOPKBOW vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.